The regulation of PD-L1 expression differs significantly between different cancer types, as well as between tumor cells and non-tumor cells due to variation of aberrations of activation of many signaling pathways such as RAS/RAF/ERK, PI3K/AKT, and JAK/STAT3, among others [41]. Here, AKT1 is linked to neoplasm.